Design and Modeling of 4-Anilinoquinazoline Derivatives as Small Molecule Inhibitors of T790M/C797S EGFR Mutations to Abandon the Phenomenon of Tumor Angiogenesis

Altaf Ahmad Shah1, Mohammad Kalim Ahmad Khan2, Salman Akhtar2, *
1 Department of Biosciences, Integral University, Lucknow 226026, Uttar Pradesh, India
2 Department of Bioengineering, Integral University, Lucknow 226026, Uttar Pradesh, India

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 516
Abstract HTML Views: 530
PDF Downloads: 1204
ePub Downloads: 175
Total Views/Downloads: 2425
Unique Statistics:

Full-Text HTML Views: 295
Abstract HTML Views: 190
PDF Downloads: 359
ePub Downloads: 140
Total Views/Downloads: 984

Creative Commons License
© 2023 Shah et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Bioengineering, Integral University, Lucknow 226026, Uttar Pradesh, India; E-mail:



In most types of cancers, specifically, lung cancer, glioblastoma, and breast cancer, the EGFR tyrosine kinase mostly remains in an overactivation state due to the developed mutations in a few specific residues of the kinase domain of protein EGFR.


The overexpression of EGFR results in the activation of signaling pathways responsible for the proliferation, growth, metastasis, and neo-angiogenesis in different types of cancers. The different mutations found in cancers expressing the EGFR include L858R, T790, and C797S and other uncommon mutations like S786R, C761X, and L861Q mutations. In the treatment with first-generation EGFR tyrosine kinase inhibitors like erlotinib and gefitinib, cancers have developed secondary resistance due to the development of secondary mutations like T790M.


It was first proposed that T790M mutations do not block the binding of the inhibitors, but later on, it was found that T790M mutations restore the ATP binding affinity of the kinase domain of EGFR monomers. Therefore, the first-generation inhibitors are not able to bind to T790M mutated EGFR. The second-generation 4-anilino quinazoline-based EGFR inhibitors like dacomitinib and afatinib have shown excellent binding potency with EGFR (T790M) but suffer serious side effects, which urges us to search for new small molecules, which may have the potential to inhibit the tumor angiogenic signals associated with over-activated EGFR.


In this study, new 4-anilino quinazoline inhibitors as small molecule inhibitors were discovered to target T790M/C797S mutations in EGFR using structure-based virtual screening, docking, and metabolic reactivity studies against the phenomenon of tumor angiogenesis.

Keywords: Tumor angiogenesis, EGFR mutations, 4-anilino quinazoline, Metastasis, Matrix metalloproteins, UCSF, Chimera.